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Abstract
Background: Understanding of immunobiology of bone marrow metastases (designated BM-
NPC) versus primary tumors (P-NPC) of the nasopharynx is far from complete. The aim of this
study was to determine if there would be differences between cultured P-NPCs and BM-NPCs with
respect to (i) constitutive IL-6 and the IL-6 receptor gp80 subunit (IL-6Rα) levels in the spent media
of nontransduced cells, and (ii) IL-6 and IL-6Rα levels in the spent media of cells transduced with a
retroviral vector containing the IFN-γ gene.
Methods: A panel of NPC cell lines were transduced with the IFN-γ gene through a retroviral
vector. Four clonal sublines were isolated via limiting dilution methods. Cytofluorometric analysis
was performed for the detection of cell surface antigens of HLA class I, HLA class II and ICAM-1.
ELISA was used to assay for IFN-γ, IL-6 and IL-6Rα in the spent media of cultured cell lines.
Results: Our results showed that in day 3 culture supernatants, low levels of soluble IL-6 were
detected in 5/5 cultured tumors derived from P-NPCs, while much higher constitutive levels of IL-
6 were detected in 3/3 metastasis-derived NPC cell lines including one originated from ascites; the
difference was significant (p = 0.025). An inverse relationship was found between IL-6Rα and IL-6
in their release levels in cultured P-NPCs and metastasis-derived NPCs. In IFN-γ-transduced-P-
NPCs, IL-6 production increased and yet IL-6Rα decreased substantially, as compared to
nontransduced counterparts. At variance with P-NPC cells, the respective ongoing IL-6 and IL-6Rα
release patterns of BM-NPC cells were not impeded as much following IFN-γ transduction. These
observations were confirmed by extended kinetic studies with representative NPC cell lines and
clonal sublines. The latter observation with the clonal sublines also indicates that selection for high
IL-6 or low IL-6Rα producing subpopulations did not occur as a result of IFN-γ-transduction
process. P-NPCs, which secreted constitutively only marginal levels of IFN-γ (8.4 ~ 10.5 pg/ml),
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transduction. Unlike P-NPCs, BM-NPCs spontaneously released IFN-γ at moderate levels (83.8 ~
100.7 pg/ml), which were enhanced by 1.3- to 2.2-fold in the spent media of their IFN-γ-transduced
counterparts.
Conclusion: Our results showed that cultured P-NPCs and BM-NPCs could be distinguished from
one another on the basis of their differential baseline secretion pattern of IFN-γ, IL-6 and IL-6Rα,
and their differential response profiles to IFN-γ gene transfer of the production of these three
soluble molecules. These results suggest that the IL-6 and IFN-γ pathways in a background of
genetic instability be involved in the acquisition of metastatic behaviour in BM-NPCs.
Background
Interferon-γ (IFN-γ) is known to function as a factor of
growth, differentiation or activation for a variety of
immune cells, such as macrophages, natural killer (NK)
cells and cytotoxic T lymphocytes (CTLs) at the site of
tumor in patients [1]. Furthermore, IFN-γ induces
enhanced expression of key immune regulatory molecules
such as class I and class II major histocompatibility com-
plex (MHC) molecules and intercellular adhesion mole-
cule-1 (ICAM-1) on the surface of tumor cells, which may
lead to improved antigen presentation to dendritic cells as
well as to pre-existing primed CTLs for further expansion
and enhanced destruction of tumor cells [2,3]. One way
toward this aim is to assure the continuous presence of
IFN-γ locally in the tumor lesion by introducing the IFN-γ
gene into the tumor cells constitutively [2-5]. The result-
ant IFN-γ production at the tumor site should specifically
increase levels of class I and class II HLA as well as ICAM-
1 expression on the tumor cells. Over the past two dec-
ades, increasing numbers of tumor rejection antigens
(processed peptides) presented by specific MHC class I
(HLA class I) molecules recognized by human T cells have
been identified not only in malignant melanoma but also
in a variety of other solid tumors including nasopharyn-
geal carcinoma (NPC) [6-8].
Human NPC, which is universally associated with
Epstein-Barr virus (EBV), is a tumor of epithelial origin
with endemic distribution among certain well-defined
ethnic groups and geographic regions [9,10]. The highest
incidence of the disease (25–50/100,000 persons per year,
accounting for approximately 30% of all cancers) has
been observed in southern Chinese, who live in Guang-
dong and Guangxi provinces as well as in a certain part of
Taiwan. NPC patients with stage I and II are usually
treated with radiotherapy alone and have a 5-year survival
rate of greater than 75%. However, a 5-year survival rate
of NPC patients with stage III or IV after radiotherapy vary
considerably, ranging from 18 ~ 52%, in spite of
improved results with combined use of radiotherapy and
chemotherapy. Patients with metastatic disease diagnosed
at the beginning of therapy almost all die within 4 years.
Thus, a more effective mode of therapy for NPC is
urgently needed. While most currently available NPC cell
lines are of local, primary tumor origin [11-14], cell lines
derived from metastatic sites are rarely available to be
studied for the understanding of the natural history and
immunotherapy of this malignancy [15]. Since bone mar-
row is one of major common metastatic sites (following
bone, lung and liver) with a reported incidence of 22%
[16], bone marrow provides an enduring reservoir and
sanctuary, from which tumor cells could spread to other
organs through the circulation. Although the importance
of micrometastatic bone marrow involvement of most
solid tumors in relation to poor prognosis has long been
recognized, the nature of these bone marrow metastatic
tumor cells has not been well defined [15,17,18]. Thus a
positive bone marrow finding for NPC cells may be a
selection criterion for adjuvant therapy for the patients
with minimal residual tumor load. The invasive pheno-
type of the tumor cells in bone marrow is reflected by their
epithelial-mesenchymal transition (EMT) and expression
of several metastasis-associated molecules, which may be
potential candidates for therapeutic targets [19,20]. We
have been interested in looking into this aspect of biolog-
ical questions, and therefore established two NPC cell
lines from bone marrow metastatic lesions. Such cell lines
established in this laboratory have been described in
detail elsewhere [15,21].
During the course of our efforts toward the development
of tumor vaccines for NPC by transfer of the IFN-γ gene to
NPC cell lines via a retroviral vector, we noted that sub-
stantial changes occurred in the levels of IL-6 and one of
its receptor subunits, gp80, commonly referred to as IL-
6Rα, released by NPC cell lines after IFN-γ transduction.
Although IL-6 is expressed and released by NPC cells to
various extents, its exact role in the process of NPC pro-
gression and bone marrow micrometastasis has largely
not been investigated [19]. In this study we describe the
distinct differences between cultured NPCs derived from
primary sites (P-NPCs) and those from bone marrow met-
astatic lesions (BM-NPCs) in regard to basal levels of IL-6
and IL-6Rα released constitutively and to the profiles of
these two soluble molecules in response to IFN-γ gene
transduction.Page 2 of 14
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Cells and culture conditions
Human NPC cell lines used were the following: NPC039
and NPC076, which both derived from NPC primary sites
[12] were gifts from Dr. C-T Lin, Department of Pathol-
ogy, National Taiwan University, Taipei, Taiwan; two
additional cell lines, CNE-1 and CNE-2 [11], originally
established from NPC primary lesions in the laboratory of
Dr. Y Zeng (Chinese Academy of Preventive Medicine,
Beijing, China) were kindly supplied to us through Dr. K-
C. Chow, China Medical University, Taichung, Taiwan,
with the permission from Dr. Y Zeng; and NPC-BR, a cell
line derived from a NPC primary site, two additional cell
lines NPC-BM1 [15,21] and NPC-BM2 [21], derived from
bone marrow metastatic lesions, were established in this
laboratory; CNE-3, also established by Dr. Y Zeng from
malignant ascites of a NPC patient in China, was a gift
from Dr. Y Zeng. Four clonal sublines, NPC039-2E2, -
6A1, -7B2 and -9A2 were isolated from the NPC039 cell
line through a limiting dilution method and the isolates
were grown and maintained in culture. NPC-BM3, a
short-term culture derived from a bone marrow metastatic
lesion from the third patient with NPC was also included
in this study.
The culture medium used was RPMI-1640 (GIBCO,
Grand Island, NY) supplemented with 1 mM sodium
pyruvate, 2 mM glutamine, 100 U/ml penicillin-G, 100
μg/ml streptomycin sulfate, and 10% fetal bovine serum
(FBS). Cultures were maintained at 37°C in an incubator
with 5% CO2, 95% air and humidified atmosphere. In the
routine maintenance of our cell lines, medium was
changed every 3 – 4 days. When growth reached near con-
fluence, cells were subcultured. Intermittently, some cells
were cryopreserved in RPMI-1640 medium containing
10% FBS and 10% dimethyl sulfoxide in liquid nitrogen.
Monoclonal antibodies
The monoclonal antibody (mAb W6/32) to a monomor-
phic determinant of HLA class I molecules associated with
β2-microglobulin was purchased from DAKO Japan Co.,
Ltd., Kyoto, Japan. Both mAb to HLA class II (clone DK22,
specific for the β-chain of all DR loci, all DP loci, DQw1
but not with DQw3 locus) and mAb to ICAM-1 (CD54)
(clone 6.5B5) were purchased from DakoCytomation,
Glostrup, Denmark.
Retroviral vectors
A vector containing the gene for human IFN-γ, the neomy-
cin phosphotransferase (neo) gene conveying resistance to
neomycin, and the LacZ gene encoding for Escherichia coli
β-galactosidase (β-Gal) was provided by Chiron Viagene
(San Diego, CA). The properties of this IFN-γ vector have
been previously described [5]. Briefly, it carried the IFN-γ
gene under the control of the murine retrovirus (Moloney
murine leukemia virus, M-MLV) long terminal repeat and
the simian virus (SV40) early promoter driving the neo-
gene. The vector was introduced to the dog cell (D17)
amphotropic packaging line known as DA. The clonal
producer line DA/IFN-γ was isolated and used to produce
a vector preparation with a titer of 5.6 × 106 colony-form-
ing units (cfu) per ml when tested on human HT-1080
cells. A similar vector, CBβ-Gal, instead of IFN-γ was used
to prepare the clonal producer line DA/CBβ-Gal, which
produced a vector preparation with a titer of approxi-
mately 5.5 × 106 cfu/ml on HT-1080 cells. Additionally, a
neovector without containing the IFN-γ gene was used as
a control. The quantity of vectors used for transduction of
each cell line or subline was expressed as a multiplicity of
infection (MOI).
Optimization of transduction conditions
A retroviral vector containing a marker gene for the
enzyme β-Gal was first transduced in order to optimize
the efficiency of transduction using cytochemical meth-
ods. In a checkerboard titration manner, tumor cells (1 ×
106) were cultured in different sets of T-75 flasks in com-
plete growth medium containing polybrene (Sigma
Chemicals, St. Louis, MO) (0.5 ~ 16 μg/ml) and β-Gal vec-
tor (1 ~ 20 cfu/cell) at different concentrations. Three days
later, transduced monolayer tumor cells were washed in
PBS, fixed with 1% formaldehyde, and stained with X-Gal.
At least 200 cells were counted to determine transduction
efficiency by the percentage of positively stained cells
exhibiting uniformly blue cytoplasm.
Retroviral transduction of the IFN-γ gene
Tumor cells (1 × 106) of a given tumor cell line, subline,
or culture were allowed to grow overnight in T-75 flasks
with RPMI-1640 medium containing 10% FBS, polybrene
at predetermined concentration and the IFN-γ vector at
predetermined (preoptimized) MOI. The following day,
G418 at the predetermined minimal concentration that
was completely lethal to neomycin-sensitive cells was
added to initiate the selection of neomycin-resistant (i.e.
transduced) cells by elimination of nontransduced cells
with that concentration of G418. After complete of the
selection, medium in flasks containing attached trans-
duced cells was replaced with fresh complete growth
medium and changed every 3 ~ 4 days thereafter. The
properties of these cell lines and clonal sublines with
respect to their origins of derivation (primary versus meta-
static lesions) and success or failure in transduction with
the retroviral vector containing IFN-γ are listed in Table 1.
Cytofluorometric analysis
Monodispersed cells harvested from monolayer cultures
by trypsinization were distributed into test tubes (5 × 105
cells/tube) and centrifuged at 400 × g to pellet the cells.
Test antibody samples (5 μg/ml; 100 μl/tube) were addedPage 3 of 14
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min. Bound antibodies were detected by fluoresencein-
isothiocyanate (FITC)-conjugated polyclonal antibodies
(goat-anti-mouse IgG; Coulter Immunology, Hialeah, FL)
in flow cytometry according to the procedures described
previously [22]. Appropriate positive and negative control
antibodies, such as anti-HLA class I (mAb W6/32), phos-
phate-buffered saline (PBS) and isotype-matched irrele-
vant mAbs were included in each experiment.
Enzyme-linked immunosorbent assay (ELISA)
ELISA kits for quantification of human IFN-γ, IL-6 and IL-
6Rα were all purchased from R&D Systems, Inc., Minne-
apolis, MN. The assays were carried out according to the
manufacturer's instructions. The limits of detectable levels
of IFN-γ, IL-6 and IL-6Rα assays were 8.0, 0.7 and 3.5 pg/
ml, respectively. The primary mAbs used in the assays
were neutralizing antibodies and therefore the cytokines
detected only bioactive IFN-γ, IL-6 and IL-6Rα. No IL-6
and IL-6Rα was detected in the fresh medium used in cul-
ture. Furthermore, we have performed experiments to
confirm the notion from the manufacture that the pres-
ence of IL-6Rα or IL-6 in the medium does not interfere
with the measurements of IL-6 or IL-6Rα, respectively,
with their assay kits.
Statistical analysis
Day 3 spent media of 8 NPC cell lines (five from primary
lesions and three from metastatic lesions) were collected
for measurements of their IL-6 and IL-6Rα secretion. The
simple linear regression analysis was performed to deter-
mine the correlation between IL-6 and logarithmic trans-
formed IL-6Rα secretion in the eight NPC cell lines. These
data were further analyzed by using of Mann-Whitney U
test to compare the secretion of IL-6 and IL-6Rα between
primary and metastatic cell lines each as a group. The p
values calculated to be less than 0.05 were considered to
indicate statistically differences between the primary and
metastatic groups. All statistic analyses were performed
with the SPSS version 13.0 (SPSS Inc., Chicago, Ill).
Results
Phenotypic characterization of the NPC cell lines
A panel of 14 NPC cell lines/sublines were tested initially,
which included 5 cell lines derived from primary lesions
(NPC039, NPC076, NPC-BR, CNE-1, CNE-2), 4 clonal
sublines derived from the NPC039 cell line (NPC039-
2E2, -6A1, -7B2, -9A2), and 5 cell lines from metastatic
lesions (CNE-3 and NPC-AS1 from ascites; NPC-BM1, -
BM2, and -BM3, the latter being a short-term culture from
different bone marrow lesions). Apart from the differ-
ences in the sensitivity to G418 killing, susceptibility to
IFN-γ transduction, these were different from one another
with respect to the extent of upregulation of HLA class I,
HLA class II and ICAM-1 expression in response to IFN-γ
transduction (Table 2). Since greater than 90% of cells in
the cell lines tested were positive for HLA class I, the rela-
tive mean fluorescence intensity (MFI) indicative of anti-
genic density on the cell surface was used to compare the
differences between nontransduced and transduced cells
Table 1: Sensitivity levels to G418 killing and success/failure in IFN-γ-transduction of a panel of NPC cell lines/sublines
Cell line/clonal subline Sensitivity to G418 killing (minimal dose for 100% cell 
kill) (μg/ml)
Success in IFN-γ gene transduction via a retroviral 
vector










Derived from a metastatic lesion
CNE-3 (ascites) 18,000 No
NPC-AS1 (ascites) 9,000 No
NPC-BM1 (bm§) 18,000 Yes
NPC-BM2 (bm) 12,000 No
NPC-BM3 (bm) 15,000 Yes
*These four sublines were clonally isolated from the NPC039 cell line.
§The abbreviation means that the cell line or culture was derived from a bone marrow metastatic lesion.Page 4 of 14
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ogeneity and individuality of these NPC cell lines exam-
ined, and in all instances where pairs of transduced and
nontransduced cells were available for direct comparison.
There was a 1.4 to 3.2-fold higher expression of surface
HLA class I antigens by the IFN-γ-transduced cells than
that by the nontransduced cells. It is of note that among
the NPC cell lines tested, HLA class II seem to be expressed
exclusively by those derived from metastatic sites, the
expression of which was upregulated on IFN-γ-transduced
cells.
Levels of IFN-γ released by IFN-γ-transduced and 
nontransduced NPC cell lines
The culture spent media of IFN-γ-transduced and non-
transduced cells of the NPC039 cell line were tested for
IFN-γ protein secretion at day 2, 3 and 4 by ELISA (Figure
1). There were only little or marginal levels of IFN-γ
detected in the spent media of cultured nontransduced
NPC039 cells at the three time points. In IFN-γ-trans-
duced NPC039 cells, IFN-γ was detected at day 2 (84.5 pg/
ml or 11.6 × 10-5 pg/cell), which remained at the similar
levels up to day 4. On the other hand, IFN-γ released into
the spent media of nontransduced NPC-BM1 cells was
readily detected at day 2 (83.8 pg/ml) and thereafter the
level remained at the similar levels ranging from 83.8 ~
100.7 pg/ml. When analyzed on per cell basis, its value
remained at the similar level over the observation period
in the range of 8.38 × 10-5 ~ 8.83 × 10-5 pg/cell (Figure 1,
right panel). In IFN-γ-transduced NPC-BM1 cells, the
amounts of IFN-γ detected at day 2 and day 3 were com-
parable in the range of 129.9 ~ 137.2 pg/ml, or 11.3 × 10-
5 ~ 12.7 × 10-5 pg/cell, the level which was increased to
209.8 pg/ml, or 19.4 × 10-5 pg/cell at day 4.
Release of IL-6 in cultured NPC cell lines derived from 
primary and metastatic lesions
We next examined the constitutive levels of IL-6 released
by eight cultured (nontransduced) NPC cell lines includ-
ing those derived from 5 primary and 3 metastatic lesions.
The spent media were collected and tested for soluble IL-
6 at day 3 cultures of NPC cell lines. Results in Figure 2
revealed that four cultured P-NPCs (NPC039, NPC076,
CNE-1, CNE-2) and one clonal sublines NPC039-2E2
released low levels of IL-6 [60.8 ± 50.7 pg/ml or (4.3 ±
3.2) × 10-5 pg/cell]. On the other hand, three metastatic
NPC cell lines (CNE-3, NPC-BM1, NPC-BM2) released
much higher levels of IL-6 [787.7 ± 522.9 pg/ml or (62.5
Table 2: Expression of surface HLA class I, HLA class II and ICAM-1 by nontransduced and IFN-γ-transduced NPC cell lines as 
determined by cytofluorometric analysis
Cell line/Subline HLA class I HLA class II ICAM-1
Derived from primary lesion
NPC039
Nontransduced 99.9 (73.0) * 0.4 99.7 (22.1)
Transduced 99.3 (231.8) 40.1 (22.0) 99.3 (61.1)
NPC076
Nontransduced 97.9 (96.8) 0.1 93.2 (16.8)
Transduced 94.1 (147.3) 28.4 (30.8) 90.8 (44.7)
NPC-BR
Nontransduced 95.8 (78.7) 0.5 95.9 (25.4)
Transduced 97.9 (139.7) 48.7 (36.2) 96.7 (50.2)
NPC039-2E2§
Nontransduced 99.9 (138.8) 0.1 86.9 (13.5)
Transduced 99.9 (179.5) 72.4 (44.0) 96.6 (30.5)
NPC039-6A1§
Nontransduced 89.5 (71.6) 2.3 (8.2) 79.1 (13.6)
Transduced 97.6 (283.0) 48.8 (47.7) 86.0 (27.3)
NPC039-7B2§
Nontransduced 99.6 (44.3) 0.9 (6.8) 90.7 (10.2)
Transduced 98.8 (88.7) 39.5 (58.0) 95.3 (23.9)
Derived from bone marrow metastasis
NPC-BM1
Nontransduced 91.2 (55.3) 26.2 (28.8) 87.8 (26.9)
Transduced 96.8 (97.6) 41.9 (28.2) 91.7 (28.8)
NPC-BM3
Nontransduced 89.4 (78.2) 18.6 (33.4) 87.1 (19.6)
Transduced 93.1 (121.6) 66.7 (50.5) 93.8 (49.2)Page 5 of 14
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groups of NPC cell lines was statistically significant.
Release of IL-6Rα in cultured NPC cell lines derived from 
primary and metastatic lesions
Experiments were set up to determine soluble IL-6Rα lev-
els in the same day 3 culture media of the eight NPC cell
lines used for the measurement of IL-6 above. Results in
Figure 3A showed that 4 P-NPC cell lines and 1 subline
derived from P-NPC released significantly higher
amounts of IL-6Rα than 3 NPC cell lines from metastatic
lesions did (609.5 ± 252.8 pg/ml versus 124.6 ± 90.1 pg/
ml). A significant difference in constitutive release profiles
of soluble IL-6Rα between cultured NPCs from primary
lesions and cultured NPCs from metastatic lesions was
also evident, when the results were expressed by pg of the
receptor per cell in the culture supernatant [(41.5 ± 17.4)
× 10-5 pg/cell versus (9.1 ± 5.4) × 10-5 pg/cell] (Figure 3B).
Secretion pattern differences in IL-6/IL-6Rα between 
cultured NPC cell lines derived from primary versus 
metastatic lesions
To evaluate the relationship between secretion of IL-6 and
IL-6Rα in these eight NPC cell lines, the observed data of
cell lines were used to construct a two-way dot plot analy-
sis for estimating whether a simple linear regression line
would fit in these two parameters. We found that as the
secretion of IL-6Rα was increased, the secretion of IL-6
was decreased in an exponential manner. Thus, a logarith-
mic transformation of IL-6 values was made to fit a simple
linear regression model. In Figure 4, a linear relationship
based on this linear regression analysis is indicated, show-
ing an inverse correlation between IL-6 and IL-6Rα (R2 =
0.772, p < 0.01).
The distributions of IL-6 and IL-6Rα secreted by NPC cell
lines derived from primary lesions (n = 5) and by NPC cell
lines from metastatic lesions (n = 3) are summarized in
Table 3. The amounts of IL-6 secreted by P-NPC cell lines
(60.8 ± 50.7 pg/ml) were clearly much less than metasta-
sis-derived NPC cell lines (787.7 ± 522.9 pg/ml). On the
other hand, the amounts of IL-6Rα secreted by P-NPC cell
lines (609.5 ± 252.8 pg/ml) were much higher than those
by metastasis-derived NPC cell lines (124.6 ± 90.1 pg/ml).
As analyzed by Mann-Whitney U test, the secretion pat-
tern of IL-6 exhibited by P-NPCs was significantly differ-
ent from that of metastasis-derived NPC cell lines (p =
Release of IFN-γ protein in the spent media by IFN-γ-transduced (T) and nontransduced parental (P) cells of the NPC039 or NPC-BM1 lineFigur 1
Release of IFN-γ protein in the spent media by IFN-γ-transduced (T) and nontransduced parental (P) cells of 
the NPC039 or NPC-BM1 line. Results of IFN-γ secreted are expressed on the basis of pg per ml and pg per cell for the 
NPC039 cell line (left panel) and the NPC-BM1 cell line (right panel).Page 6 of 14
(page number not for citation purposes)
BMC Cancer 2009, 9:169 http://www.biomedcentral.com/1471-2407/9/1690.025), so was between them with respect to the release
pattern of IL-6Rα (p = 0.025).
Differential effects of IFN-γ gene transduction on the 
kinetic secretion of soluble IL-6 and IL-6Rα from cultured 
primary NPC tumors and metastatic NPC tumors
We next examined the release of IL-6 in the spent media
from 6 cultured P-NPC cell lines in a time course study.
Low but detectable levels of IL-6 were secreted from all P-
NPC cell lines with a maximal secretion at day 1 [(11.7 ~
37.2) × 10-5 pg/cell], which were thereafter diminished
gradually to nearly undetectable down to day 4. By con-
trast, in IFN-γ-transduced cell counterparts, higher levels
of IL-6 were released progressively peaking at day 3 or 4
[(76.1 ~ 111.6) × 10-5 pg/cell]. When the patterns of IL-6
released in nontransduced and transduced cells of BM-
NPCs were compared, results were very different from
those in P-NPCs, in that gradual increases in IL-6 secretion
up to 210.5 × 10-5 pg/cell were detected as a function of
time in nontransduced BM-NPCs, peaking at day 4. More-
over, the kinetic profile of IL-6 release was essentially
unchanged following IFN-γ transduction (Figure 5). Sim-
ilar results were obtained with NPC-BM3 cells of a short-
term culture derived from a bone marrow metastatic
lesion of a different NPC patient (results not shown).
Kinetic experiments for IL-6Rα were also carried out with
the spent media of the same panel of cultured NPC cell
lines/sublines. As illustrated in Figure 6, progressively
increased levels of soluble IL-6Rα were detected in culture
supernatants of nontransduced P-NPCs with maximal lev-
els of (101.9 ~ 224.3) × 10-5 pg/cell at day 4. However, low
levels of IL-6Rα [(15.2 ~ 40.0) × 10-5 pg/cell] were
detected in IFN-γ-transduced counterparts throughout the
4 days culture period. These results suggest an association
of general suppression of IL-6Rα production with IFN-γ-
transduction in P-NPCs.
Levels of IL-6 detected in the supernatants by nontransduced NPC cell lines at day 3 culturesFigure 2
Levels of IL-6 detected in the supernatants by non-
transduced NPC cell lines at day 3 cultures. Results of 
IL-6 secreted are expressed on the basis of per ml (penal A) 
and per cell (panel B). Note that NPC039, NPC076, 
NPC039-2E2, CNE-1 and CNE-2 were derived from primary 
NPC lesions (open columns), while CNE-3 (ascites), NPC-
BM1 (bone marrow) and NPC-BM2 (bone marrow) were 
derived from different metastatic sites indicated (closed gray 
columns).
Levels of IL-6Rα detected in the spent media by nontrans-duc d NPC cell lin s a  day 3 culturesFigure 3
Levels of IL-6Rα detected in the spent media by non-
transduced NPC cell lines at day 3 cultures. Results of 
IL-6Rα secreted are expressed on the basis of per ml (penal 
A) and per cell (penal B). The penal of cell lines used were 
same as those in Figure 2.Page 7 of 14
(page number not for citation purposes)
BMC Cancer 2009, 9:169 http://www.biomedcentral.com/1471-2407/9/169IL-6 secretion patterns in IFN-γ-transduced and 
nontransduced NPC clonal sublines
There was a possibility that the inducibility of IL-6 and
suppression of IL-6Rα by IFN-γ-transduced NPC cells
derived from primary lesions demonstrated in the previ-
ous experiments could be due to the selection of poten-
tially high inducible subpopulations from the uncloned
population of a given P-NPC cell line. To rule out this pos-
sibility, kinetic studies with four additional isolated
clonal sublines NPC039-2E2, -6A1 and -7B2 were con-
ducted. The different fluctuation patterns in IL-6 and IL-
6Rα productions by nontransduced and IFN-γ-transduced
cells are consistent among P-NPC cell lines and clonal
sublines derived thereof (Figures 5 and 6), in which
results of one such clonal subline NPC039-2E2 are pre-
sented. These results and the finding of IL-6 and IL-6Rα
secretion patterns in NPC cell lines transduced with a vec-
tor of neogene without containing the IFN-γ gene resem-
bled the baseline profiles exhibited by the nontransduced
NPC cells (data not shown) exclude the possibility of
transduction-mediated selection for high IL-6 producing
or low IL-6Rα producing subpopulations.
Discussion
The identification of an expanding role for IFN-γ in the
phenotypic changes favouring for improved immuno-
genicity of neoplastic cells prompted us to search for sol-
uble or cell bound molecules associated with NPC
malignant cells, in addition to certain important mole-
cules required for immune recognition, such as ICAM-1,
HLA class I and HLA class II already documented in many
cancer systems. In this study, we found that cultured BM-
NPCs were able to constitutively produce appreciable pro-
tein levels of IFN-γ and IL-6, while cultured P-NPCs were
not. Enhanced production of IFN-γ and IL-6 were mark-
edly demonstrated in P-NPCs after they were transduced
with the IFN-γ gene, but the magnitude of enhancing
effects was much less in BM-NPCs. The most significant
finding in this current study is the differential patterns of
constitutive and response profiles of IL-6 and IL-6Rα fol-
lowing transduction with the IFN-γ gene, which clearly
discriminate between cultured P-NPCs and BM-NPCs.
Since only a limited number of NPC cell lines from dis-
tant metastatic sites other than bone marrow are currently
available, we have not yet tested them in this study. There-
fore, whether the similar differential modulation profile
of BM-NPCs to IFN-γ gene-transduction could also be
observed with other distant metastatic NPC cell lines
remains to be determined.
The results of IL-6 and IL-6Rα secretion patterns in NPC
cell lines transduced with a vector of neogene without
containing the IFN-γ gene were essentially similar to those
of the baseline profiles exhibited by the nontransduced
NPC cells. In separate experiments in which P-NPCs and
BM-NPCs were incubated independently with recom-
binant human IFN-γ at the concentrations of 100 ~ 600 U/
ml for 48 h, we have obtained similar results of fluctua-
tion in IL-6/IL-6Rα secretion as those with IFN-γ transduc-
tion (data not shown). These two lines of evidence
indicate that the gene transduction process itself was not
the cause of the changes in IL-6 and IL-6Rα secretion and
that the observed effects were indeed as the result of the
expression of the IFN-γ gene.
It has been documented that IL-6, a 184-amino acid pro-
tein with a molecular weight of 20.3 kDa was originally
described by Hirano et al. [23], is a key cytokine required
for plasma cell induction, B cell growth and antibody
Statistical analysis of the relationship between IL-6 and IL-6Rα secreted spontaneous y by NPC cell lines derive from primary and metastatic lesionsFigur  4
Statistical analysis of the relationship between IL-6 
and IL-6Rα secreted spontaneously by NPC cell lines 
derived from primary and metastatic lesions. Regres-
sion curve constructed based on the relationship between IL-
6 and IL-6Rα secreted at day 3 by all NPC cell lines tested 
including five P-NPCs (•) and three metastasis-derived NPC 
cell lines (■). The line was calculated by linear regression (r 
= 0.878; p < 0.01).
Table 3: Comparative production of IL-6/IL-6Rα by P-NPC and metastasis-derived NPC cell lines at day 3 in vitro culture
Variable P-NPC cell lines
(n = 5)
Metastasis-derived NPC cell lines
(n = 3)
p value#
IL-6 (pg/ml) 60.8 ± 50.7 † 787.7 ± 522.9 0.025
IL-6Rα (pg/ml) 609.5 ± 252.8 124.6 ± 90.1 0.025
† Results were expressed as mean ± SD. p values were calculated by using #Mann-Whitney U test for comparison of IL-6 and IL-6Rα production in 
culture.Page 8 of 14
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Kinetics of IL-6 secretion in the spent media by nontransduced and IFN-γ-transduced NPC cell lines in cultureF gure 5
Kinetics of IL-6 secretion in the spent media by nontransduced and IFN-γ-transduced NPC cell lines in culture. 
Note that NPC039, NPC039-2E2 and NPC076 were derived from primary tumor lesions, while NPC-BM1 was derived from a 
bone marrow metastatic lesion. NPC039-2E2 was a clonal subline isolated from the NPC039 cell line. Significant levels of dif-
ferences in IL-6 secretion between nontransduced and IFN-γ-transduced NPC cell lines are indicated (# p < 0.05, * p < 0.01).
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Kinetics of IL-6Rα secretion in the spent media of cultured nontransduced and IFN-γ-transduced NPC cell linesF gure 6
Kinetics of IL-6Rα secretion in the spent media of cultured nontransduced and IFN-γ-transduced NPC cell lines. 
Note that NPC039, NPC039-2E2 and NPC076 were derived from primary lesions, while NPC-BM1 was derived from a bone 
marrow metastatic lesion. NPC039-2E2 was a clonal subline isolated from the NPC039 cell line. Significant levels of differences 
in IL-6Rα secretion between nontransduced and IFN-γ-transduced NPC cell lines are indicated (# p < 0.05, * p < 0.01).
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Th2 immune responses [24]. The release of and response
to IL-6 by myeloma cells [25], melanoma cells [26], and
carcinoma cells of the head and neck [27], the breast [28]
and the kidney [29] have been reported. The role of IL-6
release into the tumor microenvironment by malignant
cells appears to vary and has been interpreted differently
depending on tumor systems: from as the indicator of
poorer prognosis, involvement in autocrine stimulatory
growth, enhanced invasiveness, to representation of Th1
and/or Th2 immune responses [30]. In an autocrine sys-
tem, IL-6 was known to regulate tumor cells proliferation
and secretion of metalloproteinases, which are involved
in tumor invasion and metastasis [31]. From the thera-
peutic standpoint, there were two studies that examined
the role of IL-6 and its receptors in promoting antitumor
responses. Porgador et al. [32] reported that the IL-6 gene
transfection into Lewis lung carcinoma cells resulted in
suppression of malignant phenotype and concomitant
endowment with immunotherapeutic competence
against parental tumor cells, signifying induction of Th1
immune response. Mackiewicz et al. [33] investigated into
the possible role of IL-6 and its receptors in activating T
cell immunity against melanoma. IL-6 exerted its activity
through a membrane-bound receptor complex consisting
of α (gp80) and β (gp130) subunits of the IL-6 receptor.
In other instances, the soluble IL-6Rα (sIL-6Rα) subunit
could often present itself as a soluble molecule, to form
many IL-6/sIL6Rα complexes first, which are in turn
attracted to two gp130 molecules (homodimers)
expressed on most of the key immune effector cells
including CD4+, CD8+ (CTLs), antigen presenting cells,
and NK cells. These interactions could lead to signal trans-
duction of immune effector cells. The proposed mecha-
nism of IL-6/sIL-6Rα complex is to activate the various
immune cells indicated via IL-6Rβ, which in combination
would lead to potent anti-tumor effects (Th1 immune
responses) [34]. In other words, IL-6 complexed with sIL-
6Rα has demonstrated qualitatively different biological
activity from IL-6 alone in stimulating long-lasting anti-
tumor immunity. Currently, we have been making efforts
to develop a sensitive and reliable assay for soluble IL-6/
IL-6Rα complex in order to study the relationship
between IL-6, IL-6Rα and IL-6/IL-6Rα complex expressed
and released by cultured NPC cells of primary and meta-
static tumor origins under IFN-γ-transduced and non-
transduced conditions.
IL-6 itself has been shown to exhibit the upregulation of
HLA class I molecules and certain tumor-associated anti-
gens such as carcinoembryonic antigen (CEA) in colon
carcinoma cells, as does IFN-γ [35,36]. Further, IL-6 could
synergize the effect of IFN-γ on the upregulation of HLA
class I and CEA when both cytokines were used in combi-
nation at concentrations 20- to 100-fold less than that
used either cytokine alone. Additionally, treatment of
colorectal tumor cells with IL-6 potentiates the IFN-γ
induction of HLA class II expression. We also demon-
strated in NPC039 cells that IL-6 could upregulate HLA
class I expression and that combined use of IL-6 and IFN-
γ, each at a lower concentration (about 25- or 57-fold less
than when IL-6 or IFN-γ was used alone) showed synergis-
tic effects on enhanced expression of surface HLA class I
molecules as compared with a single cytokine alone (Lee
M-H and Liao S-K, unpublished). A similar observation
has also been made very recently in a canine cell system
[37]. It is therefore reasonable to assume that increased
expression of HLA class I and HLA class II observed in cul-
tured NPC cells derived from primary tumors after IFN-γ
transduction must have been due to the combination
effects of both IFN-γ and IL-6. These results also suggest
that secretion of both IFN-γ and IL-6 which can be
induced by the IFN-γ gene transduction in cultured P-
NPCs should theoretically be in favour for enhanced
tumor immunogenicity, when these genetically modified
tumor cells are irradiated and administered subcutane-
ously in the autologous patients as tumor vaccines. Fur-
ther studies are required to determine which one between
cultured P-NPCs and cultured BM-NPCs could be the
ideal choice of material for the preparation of NPC tumor
vaccines. It is also important to recognize that given the
expression of new potential therapeutic targets (T cell
epitopes) that may appear in bone marrow metastatic
cells, we may have to manipulate metastatic tumor cells
differently from those derived from primary lesions in
order to make both genetically modified tumor vaccine
preparations to be therapeutically effective.
It is of interest to determine the precise mechanism by
which IL-6 gene is activated or unaltered after IFN-γ trans-
duction in cultured NPC cells from primary tumors or in
cultured NPC cells from bone marrow metastatic lesions,
respectively. It has been noted that in the early stage of
NPC pathogenesis, activation of IL-6 production in epi-
thelial cells of the nasopharynx is mediated by EBV-
encoded late membrane protein-1 (LMP-1) and CD40
through the induction of NF-κB pathway [38]. The role of
EBV in the pathogenesis of NPC has been thoroughly
reviewed [39]. Since in nearly all primary tumors in either
short-term or long-term cultures, relatively low levels of
IL-6 could be detected in the spent media, despite the fact
that no EBV DNA or EBV-encoded RNA (EBER) could be
detected after a few in vitro passages (data not shown).
This is consistent with the previous findings by others
[40], suggesting that in contrast to EBV-infected B cells in
which EBV infection persistently takes place in cultured B
cells, an in vitro environment invariably excludes the EBV
genome from epithelial cells. Nevertheless, the mecha-
nism underlying the loss of EBV genome in culture
remains illusive. It is possible that after the IL-6 gene wasPage 11 of 14
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site in vivo, this cytokine released by these epithelial cells
even at such lower concentrations appears to be required
for the maintenance of their malignant states in vitro.
Moreover, it is tempting to speculate that to establish a
micrometastasis in the bone marrow, only tumor cells
secreting high levels of IL-6 within the primary tumor cell
population may manage to survive in the new microenvi-
ronment, i.e., bone marrow, which is so different from the
primary site. Alternatively, among primary tumor cells
able to produce relatively low amounts of IL-6, only few
cells metastasize hematogenously into bone marrow cav-
ities where the IL-6 gene is reactivated to produce a high
level of IL-6 in order to survive successfully. These two
possibilities, which may not be mutually exclusive, have
yet to be investigated. In light of the importance of tumor
microenvironment in carcinogenesis and tumor progres-
sion, more attention has recently been paid to the role of
bone marrow microenvironment in tumor dissemination
[41]. Tumor cells secreting high levels of IL-6 and MIP-1α
were found to be recruited to the bone marrow, where the
balance between osteoblasts and osteoclasts was altered,
leading to a series of changes in the endosteal and vascular
niches. Further, bone marrow mesenchymal stem cells
(MSC) tend to secrete a high level of IL-6 [41-43], which
is known to play a pivotal role in the marrow space for fur-
ther tumor metastatic dissemination [43].
Both IFN-γ and IL-6 share some key factors in their signal
transduction pathways, which involve JAK tyrosine
kinases and STATs (signal transducer and activator of tran-
scription) [44]. Larner et al. [45] suggested that cytokines
such as IFN-γ activated the DNA-binding proteins whose
tyrosine residues were phosphorylated, and thus could
modulate gene expression through activation of putative
transcription factors by tyrosine-phosphorylation. The
JAK-family kinases induce tyrosine phosphorylation of
cellular transcription factors STATs, as well as their trans-
location into nucleus, thereby activating IL-6 gene [44-
47]. Two alternate models for the requirement of two JAK
kinases in the IFN signaling can be envisioned. Either
kinase functions sequentially in a cascade, or alternatively
they can function together as heterodimers to activate the
downstream signaling pathways. Activated JAKs (e.g. JAK1
and JAK3) efficiently phosphorylate the autophosphor-
ylation sites of both kinases, thus also favouring for the
cross-activation model. Our results indicate clearly that
IFN-γ transduction could merely stimulate P-NPC cells
constitutively secreting low basal levels of IL-6 to produce
much higher levels of IL-6, but could not stimulate BM-
NPC cells that have constitutively been able to secrete this
cytokine and IFN-γ in higher levels, to further release addi-
tional IL-6. This discrepancy is very likely to involve the
differences in the utility of factors, such as JAK1, JAK2,
JAK3, Tyk2, NF-κB, IFN regulatory factor 1 (IRF-1) and/or
STATs (e.g. STAT-1 activated by IFN-γ; STAT-3 activated by
IL-6), thereby creating a positive and a negative regulation
for P-NPC and BM-NPC cells respectively [47]. In other
words, the mechanism underlying the relative resistance
of BM-NPC cells to be enhanced to secrete IL-6 in a much
higher magnitude like P-NPC cells is possibly due to the
insensitivity to the ongoing cooperation of IRF-1 and the
p65 subunit of NK-κB for IL-6 activation at the level of IL-
6 promoter by IFN-γ [45]. In this context, recent reports
on the newly identified role of IL-6 in epithelial cancer,
such as breast and lung carcinomas, are intriguing in that
IL-6 has been implicated in tumorigenesis via the IL-6
receptor-activation-mediated phosphorylation of STAT3
[48,49] and that release of IL-6 results in a positive feed-
back loop causing further IL-6 upregulation and secretion.
Following binding of this cytokine and its receptor, IL-
6Rβ, causes upregulation of Notch-3 ligand Jagged 1,
which triggers the upregulation of carbonic anhydrase IX
(CA-IX), such changes leading to promote malignant fea-
tures of cancer stem cells [28]. These results also suggest
that the IL-6 and IFN-γ pathways in a background of
genetic instability be involved in the acquisition of meta-
static behaviour in BM-NPCs. This may be one of the rea-
sons why the approach of IFN-γ-modified tumor cells has
gradually been phased out from the list of cancer vaccines
over the past decade. Finally, one should bear in mind
that the role of EBV is not evoked in the present study with
the use of the NPC cell lines investigated.
Conclusion
Our present study has demonstrated that in NPC asides
from the difference in drug sensitivity to G418 and expres-
sion of surface HLA class II (Table 1), the baseline and
response profiles to IFN-γ transduction of IL-6 and IL-6Rα
are also found to be different between cultured P-NPCs
and BM-NPCs. Our results stress the importance to evalu-
ate the endogenous levels of IL-6 and IL-6Rα in each NPC
individually, if cultured NPC cells of the given tumor are
to be considered for making tumor vaccines. Finally, the
precise mechanism behind the activation of IL-6 and con-
comitant suppression of IL-6Rα expression in P-NPCs fol-
lowing IFN-γ transduction and why such a phenomenon
in P-NPCs is so different from that of BM-NPCs are still
the issues as yet to be explored. This resulting information
is important in our better understanding of NPC biology,
specifically, the role of IL-6 secretion in NPC progression
and bone marrow micrometastasis.
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